Castrate-resistant prostate cancer market by The rapy- Global Industry Analysis & Forecast to 2027
Published On : January 2021 Pages : 145 Category: Pharma & Healthcare Report Code : HC0114945
Castrate-resistant prostate cancer market By Therapy (Chemotherapy, Hormonal Therapy, Immunotherapy, Radiotherapy) - Global Industry Analysis & Forecast to 2027
Industry Outlook and Trend Analysis
The Castrate-resistant prostate cancer markethas encountered significant development over the recent years and is anticipated to grow tremendously over the forecast period.Castrate-resistant prostate cancer is a type of cancer that stops responding to hormone therapy. PSA is a protein produced by prostate cancer cells. If PSA levels start to rise while you are on hormone therapy, this can be a sign that the treatment has stopped working and the cancer has become castrate resistant.
Drivers and Restraints
Top-down and bottom-up approaches are used to validate the global Castrate-resistant prostate cancer market and estimate the market size for company, regions segments, type segments and applications (end users). In the complete market engineering process, both top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub segments listed in this report. Extensive qualitative and further quantitative analysis is also done from all the numbers arrived at in the complete market engineering process to list key information throughout the report.
Regional Insights
The data for 2021 is an estimate, based on the history data and the integrated view of industry experts, manufacturers, distributors and end users etc.
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Southeast Asia
- Rest of Asia-Pacific
- SouthAmerica
- Brazil
- Argentina
- Columbia
- Rest of South America
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Nigeria
- South Africa
- Turkey
- Rest of MEA
Competitive Analysis
The major players in the market are profiled in detail in view of qualities, for example, company portfolio, business strategies, financial overview, recent developments, and share of the overall industry.
- Sanofi
- Johnson & Johnson Services, Inc.
- Pfizer, Inc.
- Astellas Pharma, Inc.
- Bayer AG
Some of the key questions answered by the report are:
- What was the market size in 2017 and forecast from 2021 to 2027?
- What will be the industry market growth from 2017 to 2027?
- What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
- What are the major segments leading the market growth and why?
- Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?
Market Classification
· Castrate-resistant prostate cancer market, ByTherapy, Estimates and Forecast, 2017-2027 ($Million)
o Chemotherapy
o Hormonal Therapy
o Immunotherapy
o Radiotherapy
· Castrate-resistant prostate cancer market, By Key Players, Estimates and Forecast, 2017-2027 ($Million)
o Sanofi
o Johnson & Johnson Services, Inc.
o Pfizer, Inc.
o Astellas Pharma, Inc.
o Bayer AG
· Castrate-resistant prostate cancer market, By Region, Estimates and Forecast, 2017-2027 ($Million)
o North America
§ North America Castrate-resistant prostate cancer market, By Country
o U.S. Castrate-resistant prostate cancer market
o Canada Castrate-resistant prostate cancer market
o Mexico Castrate-resistant prostate cancer market
o Europe
§ Europe Castrate-resistant prostate cancer market, By Country
o UK Castrate-resistant prostate cancer market
o Germany Castrate-resistant prostate cancer market
o France Castrate-resistant prostate cancer market
o Russia Castrate-resistant prostate cancer market
o Italy Castrate-resistant prostate cancer market
o Rest of Europe Castrate-resistant prostate cancer market
o Asia-Pacific
§ Asia-Pacific Castrate-resistant prostate cancer market, By Country
o China Castrate-resistant prostate cancer market
o Japan Castrate-resistant prostate cancer market
o South Korea Castrate-resistant prostate cancer market
o India Castrate-resistant prostate cancer market
o Southeast Asia Castrate-resistant prostate cancer market
o Rest of Asia-Pacific Castrate-resistant prostate cancer market
o South America
§ South America Castrate-resistant prostate cancer market
o Brazil Castrate-resistant prostate cancer market
o Argentina Castrate-resistant prostate cancer market
o Columbia Castrate-resistant prostate cancer market
o Rest of South America Castrate-resistant prostate cancer market
o Middle East and Africa
§ Middle East and Africa Castrate-resistant prostate cancer market
o Saudi Arabia Castrate-resistant prostate cancer market
o UAE Castrate-resistant prostate cancer market
o Egypt Castrate-resistant prostate cancer market
o Nigeria Castrate-resistant prostate cancer market
o South Africa Castrate-resistant prostate cancer market
o TurkeyCastrate-resistant prostate cancer market
o Rest of MEA Castrate-resistant prostate cancer market
1. Introduction
1.1. Report Description
2. Executive Summary
2.1. Key Highlights
3. Market Overview
3.1. Introduction
3.1.1. Market Definition
3.1.2. Market Segmentation
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
4. Market Analysis by Regions
4.1. North America (United States, Canada and Mexico)
4.1.1. United States Market Status and Outlook (2017-2027)
4.1.2. Canada Market Status and Outlook (2017-2027)
4.1.3. Mexico Market Status and Outlook (2017-2027)
4.2. Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
4.2.1. Germany Market Status and Outlook (2017-2027)
4.2.2. France Market Status and Outlook (2017-2027)
4.2.3. UK Market Status and Outlook (2017-2027)
4.2.4. Russia Market Status and Outlook (2017-2027)
4.2.5. Italy Market Status and Outlook (2017-2027)
4.2.6. Rest of Europe Market Status and Outlook (2017-2027)
4.3. Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Rest of Asia-Pacific)
4.3.1. China Market Status and Outlook (2017-2027)
4.3.2. Japan Market Status and Outlook (2017-2027)
4.3.3. Korea Market Status and Outlook (2017-2027)
4.3.4. India Market Status and Outlook (2017-2027)
4.3.5. Southeast Asia Market Status and Outlook (2017-2027)
4.3.6. Rest of Asia-Pacific Market Status and Outlook (2017-2027)
4.4. South America (Brazil, Argentina, Columbia and Rest of South America)
4.4.1. Brazil Market Status and Outlook (2017-2027)
4.4.2. Argentina Market Status and Outlook (2017-2027)
4.4.3. Columbia Market Status and Outlook (2017-2027)
4.4.4. Rest of South America Market Status and Outlook (2017-2027)
4.5. Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of MEA)
4.5.1. Saudi Arabia Market Status and Outlook (2017-2027)
4.5.2. United Arab Emirates Market Status and Outlook (2017-2027)
4.5.3. Egypt Market Status and Outlook (2017-2027)
4.5.4. Nigeria Market Status and Outlook (2017-2027)
4.5.5. South Africa Market Status and Outlook (2017-2027)
4.5.6. Turkey Market Status and Outlook (2017-2027)
4.5.7. Rest of Middle East and Africa Market Status and Outlook (2017-2027)
5. Castrate-resistant Prostate Cancer Market, By Therapy
5.1. Introduction
5.2. Global Castrate-resistant Prostate Cancer Revenue and Market Share by Therapy (2017-2021)
5.2.1. Global Castrate-resistant Prostate Cancer Revenue and Revenue Share by Therapy (2017-2021)
5.3. Chemotherapy
5.3.1. Global Chemotherapy Revenue and Growth Rate (2017-2021)
5.4. Hormonal Therapy
5.4.1. Global Hormonal Therapy Revenue and Growth Rate (2017-2021)
5.5. Immunotherapy
5.5.1. Global Immunotherapy Revenue and Growth Rate (2017-2021)
5.6. Radiotherapy
5.6.1. Global Radiotherapy Revenue and Growth Rate (2017-2021)
6. Castrate-resistant Prostate Cancer Market, By Region
6.1. Introduction
6.2. Global Castrate-resistant Prostate Cancer Revenue and Market Share by Regions
6.2.1. Global Castrate-resistant Prostate Cancer Revenue by Regions (2017-2021)
6.3. North America Castrate-resistant Prostate Cancer by Countries
6.3.1. North America Castrate-resistant Prostate Cancer Revenue and Growth Rate (2017-2021)
6.3.2. North America Castrate-resistant Prostate Cancer Revenue (Million USD) by Countries (2017-2021)
6.3.3. United States
6.3.3.1. United States Castrate-resistant Prostate Cancer Revenue (Millions USD) and Growth Rate (2017-2021)
6.3.4. Canada
6.3.4.1. Canada Castrate-resistant Prostate Cancer Revenue (Millions USD) and Growth Rate (2017-2021)
6.3.5. Mexico
6.3.5.1. Mexico Castrate-resistant Prostate Cancer Revenue (Millions USD) and Growth Rate (2017-2021)
6.4. Europe Castrate-resistant Prostate Cancer by Countries
6.4.1. Europe Castrate-resistant Prostate Cancer Revenue and Growth Rate (2017-2021)
6.4.2. Europe Castrate-resistant Prostate Cancer Revenue (Million USD) by Countries (2017-2021)
6.4.3. Germany
6.4.3.1. Germany Castrate-resistant Prostate Cancer Revenue (Millions USD) and Growth Rate (2017-2021)
6.4.4. France
6.4.4.1. France Castrate-resistant Prostate Cancer Revenue (Millions USD) and Growth Rate (2017-2021)
6.4.5. UK
6.4.5.1. UK Castrate-resistant Prostate Cancer Revenue (Millions USD) and Growth Rate (2017-2021)
6.4.6. Russia
6.4.6.1. Russia Castrate-resistant Prostate Cancer Revenue (Millions USD) and Growth Rate (2017-2021)
6.4.7. Italy
6.4.7.1. Italy Castrate-resistant Prostate Cancer Revenue (Millions USD) and Growth Rate (2017-2021)
6.4.8. Rest of Europe
6.4.8.1. Rest of Europe Castrate-resistant Prostate Cancer Revenue (Millions USD) and Growth Rate (2017-2021)
6.5. Asia-Pacific Castrate-resistant Prostate Cancer by Countries
6.5.1. Asia-Pacific Castrate-resistant Prostate Cancer Revenue and Growth Rate (2017-2021)
6.5.2. Asia-Pacific Castrate-resistant Prostate Cancer Revenue (Million USD) by Countries (2017-2021)
6.5.3. China
6.5.3.1. China Castrate-resistant Prostate Cancer Revenue (Millions USD) and Growth Rate (2017-2021)
6.5.4. Japan
6.5.4.1. Japan Castrate-resistant Prostate Cancer Revenue (Millions USD) and Growth Rate (2017-2021)
6.5.5. Korea
6.5.5.1. Korea Castrate-resistant Prostate Cancer Revenue (Millions USD) and Growth Rate (2017-2021)
6.5.6. India
6.5.6.1. India Castrate-resistant Prostate Cancer Revenue (Millions USD) and Growth Rate (2017-2021)
6.5.7. Southeast Asia
6.5.7.1. Southeast Asia Castrate-resistant Prostate Cancer Revenue (Millions USD) and Growth Rate (2017-2021)
6.5.8. Rest of Asia-Pacific
6.5.8.1. Rest of Asia-Pacific Castrate-resistant Prostate Cancer Revenue (Millions USD) and Growth Rate (2017-2021)
6.6. South America Castrate-resistant Prostate Cancer by Countries
6.6.1. South America Castrate-resistant Prostate Cancer Revenue and Growth Rate (2017-2021)
6.6.2. South America Castrate-resistant Prostate Cancer Revenue (Million USD) by Countries (2017-2021)
6.6.3. Brazil
6.6.3.1. Brazil Castrate-resistant Prostate Cancer Revenue (Millions USD) and Growth Rate (2017-2021)
6.6.4. Argentina
6.6.4.1. Argentina Castrate-resistant Prostate Cancer Revenue (Millions USD) and Growth Rate (2017-2021)
6.6.5. Columbia
6.6.5.1. Columbia Castrate-resistant Prostate Cancer Revenue (Millions USD) and Growth Rate (2017-2021)
6.6.6. Rest of South America
6.6.6.1. Rest of South America Castrate-resistant Prostate Cancer Revenue (Millions USD) and Growth Rate (2017-2021)
6.7. Middle East and Africa Castrate-resistant Prostate Cancer by Countries
6.7.1. Middle East and Africa Castrate-resistant Prostate Cancer Revenue and Growth Rate (2017-2021)
6.7.2. Middle East and Africa Castrate-resistant Prostate Cancer Revenue (Million USD) by Countries (2017-2021)
6.7.3. Saudi Arabia
6.7.3.1. Saudi Arabia Castrate-resistant Prostate Cancer Revenue (Millions USD) and Growth Rate (2017-2021)
6.7.4. United Arab Emirates
6.7.4.1. United Arab Emirates Castrate-resistant Prostate Cancer Revenue (Millions USD) and Growth Rate (2017-2021)
6.7.5. Egypt
6.7.5.1. Egypt Castrate-resistant Prostate Cancer Revenue (Millions USD) and Growth Rate (2017-2021)
6.7.6. Nigeria
6.7.6.1. Nigeria Castrate-resistant Prostate Cancer Revenue (Millions USD) and Growth Rate (2017-2021)
6.7.7. South Africa
6.7.7.1. South Africa Castrate-resistant Prostate Cancer Revenue (Millions USD) and Growth Rate (2017-2021)
6.7.8. Turkey
6.7.8.1. Turkey Castrate-resistant Prostate Cancer Revenue (Millions USD) and Growth Rate (2017-2021)
6.7.9. Rest of Middle East and Africa
6.7.9.1. Rest of Middle East and Africa Castrate-resistant Prostate Cancer Revenue (Millions USD) and Growth Rate (2017-2021)
7. Company Profiles
7.1. Sanofi
7.1.1. Business Overview
7.1.2. Service Portfolio
7.1.3. Strategic Developments
7.1.4. Financial Overview
7.2. Johnson & Johnson Services, Inc.
7.2.1. Business Overview
7.2.2. Service Portfolio
7.2.3. Strategic Developments
7.2.4. Financial Overview
7.3. Pfizer, Inc.
7.3.1. Business Overview
7.3.2. Service Portfolio
7.3.3. Strategic Developments
7.3.4. Financial Overview
7.4. Astellas Pharma, Inc.
7.4.1. Business Overview
7.4.2. Service Portfolio
7.4.3. Strategic Developments
7.4.4. Financial Overview
7.5. Bayer AG
7.5.1. Business Overview
7.5.2. Service Portfolio
7.5.3. Strategic Developments
7.5.4. Financial Overview
8. Castrate-resistant Prostate Cancer Market Forecast (2022-2027)
8.1. Global Castrate-resistant Prostate Cancer Revenue (Millions USD) and Growth Rate (2022-2027)
8.2. Castrate-resistant Prostate Cancer Market Forecast by Regions (2022-2027)
8.2.1. North America Castrate-resistant Prostate Cancer Market Forecast (2022-2027)
8.2.1.1. United States Castrate-resistant Prostate Cancer Market Forecast (2022-2027)
8.2.1.2. Canada Castrate-resistant Prostate Cancer Market Forecast (2022-2027)
8.2.1.3. Mexico Castrate-resistant Prostate Cancer Market Forecast (2022-2027)
8.2.2. Europe Castrate-resistant Prostate Cancer Market Forecast (2022-2027)
8.2.2.1. Germany Castrate-resistant Prostate Cancer Market Forecast (2022-2027)
8.2.2.2. France Castrate-resistant Prostate Cancer Market Forecast (2022-2027)
8.2.2.3. UK Castrate-resistant Prostate Cancer Market Forecast (2022-2027)
8.2.2.4. Russia Castrate-resistant Prostate Cancer Market Forecast (2022-2027)
8.2.2.5. Italy Castrate-resistant Prostate Cancer Market Forecast (2022-2027)
8.2.2.6. Rest of Europe Castrate-resistant Prostate Cancer Market Forecast (2022-2027)
8.2.3. Asia-Pacific Castrate-resistant Prostate Cancer Market Forecast (2022-2027)
8.2.3.1. China Castrate-resistant Prostate Cancer Market Forecast (2022-2027)
8.2.3.2. Japan Castrate-resistant Prostate Cancer Market Forecast (2022-2027)
8.2.3.3. Korea Castrate-resistant Prostate Cancer Market Forecast (2022-2027)
8.2.3.4. India Castrate-resistant Prostate Cancer Market Forecast (2022-2027)
8.2.3.5. Southeast Asia Castrate-resistant Prostate Cancer Market Forecast (2022-2027)
8.2.3.6. Rest of Asia-Pacific Castrate-resistant Prostate Cancer Market Forecast (2022-2027)
8.2.4. South America Castrate-resistant Prostate Cancer Market Forecast (2022-2027)
8.2.4.1. Brazil Castrate-resistant Prostate Cancer Market Forecast (2022-2027)
8.2.4.2. Argentina Castrate-resistant Prostate Cancer Market Forecast (2022-2027)
8.2.4.3. Columbia Castrate-resistant Prostate Cancer Market Forecast (2022-2027)
8.2.4.4. Rest of South America Castrate-resistant Prostate Cancer Market Forecast (2022-2027)
8.2.5. Middle East and Africa Castrate-resistant Prostate Cancer Market Forecast (2022-2027)
8.2.5.1. Saudi Arabia Castrate-resistant Prostate Cancer Market Forecast (2022-2027)
8.2.5.2. United Arab Emirates Castrate-resistant Prostate Cancer Market Forecast (2022-2027)
8.2.5.3. Egypt Castrate-resistant Prostate Cancer Market Forecast (2022-2027)
8.2.5.4. Nigeria Castrate-resistant Prostate Cancer Market Forecast (2022-2027)
8.2.5.5. South Africa Castrate-resistant Prostate Cancer Market Forecast (2022-2027)
8.2.5.6. Turkey Castrate-resistant Prostate Cancer Market Forecast (2022-2027)
8.2.5.7. Rest of Middle East and Africa Castrate-resistant Prostate Cancer Market Forecast (2022-2027)
8.3. Castrate-resistant Prostate Cancer Market Forecast by Therapy (2022-2027)
8.3.1. Castrate-resistant Prostate Cancer Forecast by Therapy (2022-2027)
8.3.2. Castrate-resistant Prostate Cancer Market Share Forecast by Therapy (2022-2027)
List of Tables
List of Tables and Figures:
Figure United States Castrate-resistant Prostate Cancer Revenue (Million USD) and Growth Rate (2017-2027)
Figure Canada Castrate-resistant Prostate Cancer Revenue (Million USD) and Growth Rate (2017-2027)
Figure Mexico Castrate-resistant Prostate Cancer Revenue (Million USD) and Growth Rate (2017-2027)
Figure Germany Castrate-resistant Prostate Cancer Revenue (Million USD) and Growth Rate (2017-2027)
Figure France Castrate-resistant Prostate Cancer Revenue (Million USD) and Growth Rate (2017-2027)
Figure UK Castrate-resistant Prostate Cancer Revenue (Million USD) and Growth Rate (2017-2027)
Figure Russia Castrate-resistant Prostate Cancer Revenue (Million USD) and Growth Rate (2017-2027)
Figure Italy Castrate-resistant Prostate Cancer Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of Europe Castrate-resistant Prostate Cancer Revenue (Million USD) and Growth Rate (2017-2027)
Figure China Castrate-resistant Prostate Cancer Revenue (Million USD) and Growth Rate (2017-2027)
Figure Japan Castrate-resistant Prostate Cancer Revenue (Million USD) and Growth Rate (2017-2027)
Figure Korea Castrate-resistant Prostate Cancer Revenue (Million USD) and Growth Rate (2017-2027)
Figure India Castrate-resistant Prostate Cancer Revenue (Million USD) and Growth Rate (2017-2027)
Figure Southeast Asia Castrate-resistant Prostate Cancer Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of Asia-Pacific Castrate-resistant Prostate Cancer Revenue (Million USD) and Growth Rate (2017-2027)
Figure Brazil Castrate-resistant Prostate Cancer Revenue (Million USD) and Growth Rate (2017-2027)
Figure Argentina Castrate-resistant Prostate Cancer Revenue (Million USD) and Growth Rate (2017-2027)
Figure Columbia Castrate-resistant Prostate Cancer Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of South America Castrate-resistant Prostate Cancer Revenue (Million USD) and Growth Rate (2017-2027)
Figure Saudi Arabia Castrate-resistant Prostate Cancer Revenue (Million USD) and Growth Rate (2017-2027)
Figure United Arab Emirates Castrate-resistant Prostate Cancer Revenue (Million USD) and Growth Rate (2017-2027)
Figure Egypt Castrate-resistant Prostate Cancer Revenue (Million USD) and Growth Rate (2017-2027)
Figure Nigeria Castrate-resistant Prostate Cancer Revenue (Million USD) and Growth Rate (2017-2027)
Figure South Africa Castrate-resistant Prostate Cancer Revenue (Million USD) and Growth Rate (2017-2027)
Figure Turkey Castrate-resistant Prostate Cancer Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of Middle East and Africa Castrate-resistant Prostate Cancer Revenue (Million USD) and Growth Rate (2017-2027)
Table Global Castrate-resistant Prostate Cancer Revenue and Revenue Share by Therapy (2017-2019)
Figure Global Chemotherapy Revenue and Growth Rate (2017-2019)
Figure Global Hormonal Therapy Revenue and Growth Rate (2017-2019)
Figure Global Immunotherapy Revenue and Growth Rate (2017-2019)
Figure Global Radiotherapy Revenue and Growth Rate (2017-2019)
Table Global Castrate-resistant Prostate Cancer Revenue by Regions (2017-2019)
Figure North America Castrate-resistant Prostate Cancer Growth Rate (2017-2019)
Figure North America Castrate-resistant Prostate Cancer Revenue and Growth Rate (2017-2019)
Figure North America Castrate-resistant Prostate Cancer by Countries (2017-2019)
Figure North America Castrate-resistant Prostate Cancer Revenue (Million USD) by Countries (2017-2019)
Figure United States Castrate-resistant Prostate Cancer Growth Rate (2017-2019)
Figure United States Castrate-resistant Prostate Cancer Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Canada Castrate-resistant Prostate Cancer Growth Rate (2017-2019)
Figure Canada Castrate-resistant Prostate Cancer Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Mexico Castrate-resistant Prostate Cancer Growth Rate (2017-2019)
Figure Mexico Castrate-resistant Prostate Cancer Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Europe Castrate-resistant Prostate Cancer Growth Rate (2017-2019)
Figure Europe Castrate-resistant Prostate Cancer Revenue and Growth Rate (2017-2019)
Figure Europe Castrate-resistant Prostate Cancer by Countries (2017-2019)
Figure Europe Castrate-resistant Prostate Cancer Revenue (Million USD) by Countries (2017-2019)
Figure Germany Castrate-resistant Prostate Cancer Growth Rate (2017-2019)
Figure Germany Castrate-resistant Prostate Cancer Revenue (Millions USD) and Growth Rate (2017-2019)
Figure France Castrate-resistant Prostate Cancer Growth Rate (2017-2019)
Figure France Castrate-resistant Prostate Cancer Revenue (Millions USD) and Growth Rate (2017-2019)
Figure UK Castrate-resistant Prostate Cancer Growth Rate (2017-2019)
Figure UK Castrate-resistant Prostate Cancer Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Russia Castrate-resistant Prostate Cancer Growth Rate (2017-2019)
Figure Russia Castrate-resistant Prostate Cancer Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Italy Castrate-resistant Prostate Cancer Growth Rate (2017-2019)
Figure Italy Castrate-resistant Prostate Cancer Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Rest of Europe Castrate-resistant Prostate Cancer Growth Rate (2017-2019)
Figure Rest of Europe Castrate-resistant Prostate Cancer Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Asia-Pacific Castrate-resistant Prostate Cancer Growth Rate (2017-2019)
Figure Asia-Pacific Castrate-resistant Prostate Cancer Revenue and Growth Rate (2017-2019)
Figure Asia-Pacific Castrate-resistant Prostate Cancer by Countries (2017-2019)
Figure Asia-Pacific Castrate-resistant Prostate Cancer Revenue (Million USD) by Countries (2017-2019)
Figure China Castrate-resistant Prostate Cancer Growth Rate (2017-2019)
Figure China Castrate-resistant Prostate Cancer Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Japan Castrate-resistant Prostate Cancer Growth Rate (2017-2019)
Figure Japan Castrate-resistant Prostate Cancer Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Korea Castrate-resistant Prostate Cancer Growth Rate (2017-2019)
Figure Korea Castrate-resistant Prostate Cancer Revenue (Millions USD) and Growth Rate (2017-2019)
Figure India Castrate-resistant Prostate Cancer Growth Rate (2017-2019)
Figure India Castrate-resistant Prostate Cancer Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Southeast Asia Castrate-resistant Prostate Cancer Growth Rate (2017-2019)
Figure Southeast Asia Castrate-resistant Prostate Cancer Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Rest of Asia-Pacific Castrate-resistant Prostate Cancer Growth Rate (2017-2019)
Figure Rest of Asia-Pacific Castrate-resistant Prostate Cancer Revenue (Millions USD) and Growth Rate (2017-2019)
Figure South America Castrate-resistant Prostate Cancer Growth Rate (2017-2019)
Figure South America Castrate-resistant Prostate Cancer Revenue and Growth Rate (2017-2019)
Figure South America Castrate-resistant Prostate Cancer by Countries (2017-2019)
Figure South America Castrate-resistant Prostate Cancer Revenue (Million USD) by Countries (2017-2019)
Figure Brazil Castrate-resistant Prostate Cancer Growth Rate (2017-2019)
Figure Brazil Castrate-resistant Prostate Cancer Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Argentina Castrate-resistant Prostate Cancer Growth Rate (2017-2019)
Figure Argentina Castrate-resistant Prostate Cancer Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Columbia Castrate-resistant Prostate Cancer Growth Rate (2017-2019)
Figure Columbia Castrate-resistant Prostate Cancer Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Rest of South America Castrate-resistant Prostate Cancer Growth Rate (2017-2019)
Figure Rest of South America Castrate-resistant Prostate Cancer Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Middle East and Africa Castrate-resistant Prostate Cancer Growth Rate (2017-2019)
Figure Middle East and Africa Castrate-resistant Prostate Cancer Revenue and Growth Rate (2017-2019)
Figure Middle East and Africa Castrate-resistant Prostate Cancer by Countries (2017-2019)
Figure Middle East and Africa Castrate-resistant Prostate Cancer Revenue (Million USD) by Countries (2017-2019)
Figure Saudi Arabia Castrate-resistant Prostate Cancer Growth Rate (2017-2019)
Figure Saudi Arabia Castrate-resistant Prostate Cancer Revenue (Millions USD) and Growth Rate (2017-2019)
Figure United Arab Emirates Castrate-resistant Prostate Cancer Growth Rate (2017-2019)
Figure United Arab Emirates Castrate-resistant Prostate Cancer Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Egypt Castrate-resistant Prostate Cancer Growth Rate (2017-2019)
Figure Egypt Castrate-resistant Prostate Cancer Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Nigeria Castrate-resistant Prostate Cancer Growth Rate (2017-2019)
Figure Nigeria Castrate-resistant Prostate Cancer Revenue (Millions USD) and Growth Rate (2017-2019)
Figure South Africa Castrate-resistant Prostate Cancer Growth Rate (2017-2019)
Figure South Africa Castrate-resistant Prostate Cancer Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Turkey Castrate-resistant Prostate Cancer Growth Rate (2017-2019)
Figure Turkey Castrate-resistant Prostate Cancer Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Rest of Middle East and Africa Castrate-resistant Prostate Cancer Growth Rate (2017-2019)
Figure Rest of Middle East and Africa Castrate-resistant Prostate Cancer Revenue (Millions USD) and Growth Rate (2017-2019)
Table Sanofi Castrate-resistant Prostate Cancer Financial Overview
Table Johnson & Johnson Services, Inc. Castrate-resistant Prostate Cancer Financial Overview
Table Pfizer, Inc. Castrate-resistant Prostate Cancer Financial Overview
Table Astellas Pharma, Inc. Castrate-resistant Prostate Cancer Financial Overview
Table Bayer AG Castrate-resistant Prostate Cancer Financial Overview
Figure Global Castrate-resistant Prostate Cancer Revenue (Millions USD) and Growth Rate (2019-2027)
Table Castrate-resistant Prostate Cancer Market Forecast by Regions (2019-2027)
Figure North America Castrate-resistant Prostate Cancer Market Forecast (2019-2027)
Figure United States Castrate-resistant Prostate Cancer Market Forecast (2019-2027)
Figure Canada Castrate-resistant Prostate Cancer Market Forecast (2019-2027)
Figure Mexico Castrate-resistant Prostate Cancer Market Forecast (2019-2027)
Figure Europe Castrate-resistant Prostate Cancer Market Forecast (2019-2027)
Figure Germany Castrate-resistant Prostate Cancer Market Forecast (2019-2027)
Figure France Castrate-resistant Prostate Cancer Market Forecast (2019-2027)
Figure UK Castrate-resistant Prostate Cancer Market Forecast (2019-2027)
Figure Russia Castrate-resistant Prostate Cancer Market Forecast (2019-2027)
Figure Italy Castrate-resistant Prostate Cancer Market Forecast (2019-2027)
Figure Rest of Europe Castrate-resistant Prostate Cancer Market Forecast (2019-2027)
Figure Asia-Pacific Castrate-resistant Prostate Cancer Market Forecast (2019-2027)
Figure China Castrate-resistant Prostate Cancer Market Forecast (2019-2027)
Figure Japan Castrate-resistant Prostate Cancer Market Forecast (2019-2027)
Figure Korea Castrate-resistant Prostate Cancer Market Forecast (2019-2027)
Figure India Castrate-resistant Prostate Cancer Market Forecast (2019-2027)
Figure Southeast Asia Castrate-resistant Prostate Cancer Market Forecast (2019-2027)
Figure Rest of Asia-Pacific Castrate-resistant Prostate Cancer Market Forecast (2019-2027)
Figure South America Castrate-resistant Prostate Cancer Market Forecast (2019-2027)
Figure Brazil Castrate-resistant Prostate Cancer Market Forecast (2019-2027)
Figure Argentina Castrate-resistant Prostate Cancer Market Forecast (2019-2027)
Figure Columbia Castrate-resistant Prostate Cancer Market Forecast (2019-2027)
Figure Rest of South America Castrate-resistant Prostate Cancer Market Forecast (2019-2027)
Figure Middle East and Africa Castrate-resistant Prostate Cancer Market Forecast (2019-2027)
Figure Saudi Arabia Castrate-resistant Prostate Cancer Market Forecast (2019-2027)
Figure United Arab Emirates Castrate-resistant Prostate Cancer Market Forecast (2019-2027)
Figure Egypt Castrate-resistant Prostate Cancer Market Forecast (2019-2027)
Figure Nigeria Castrate-resistant Prostate Cancer Market Forecast (2019-2027)
Figure South Africa Castrate-resistant Prostate Cancer Market Forecast (2019-2027)
Figure Turkey Castrate-resistant Prostate Cancer Market Forecast (2019-2027)
Figure Rest of Middle East and Africa Castrate-resistant Prostate Cancer Market Forecast (2019-2027)
Figure Global Castrate-resistant Prostate Cancer Forecast by Therapy (2019-2027)
Figure Global Castrate-resistant Prostate Cancer Market Share Forecast by Therapy (2019-2027)
Figure Global Castrate-resistant Prostate Cancer Forecast by Therapy (2019-2027)
Please Note: Data related to the Companies are subject to Availability.
Research Methodology
We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.
Data Mining
Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.
Data Collection Matrix
|
Data Collection Matrix |
Supply Side |
Demand Side |
|
Primary Data Sources |
|
|
|
Secondary Data Sources |
|
|
Market Modeling and Forecasting
We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.
- Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
- Number of patients for particular device or medical procedure and
- Repeated use of particular device depending on health and condition of patient
- Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.
We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.
Data Validation
We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.
Data Triangulation
Industry Analysis
|
Qualitative Data |
Quantitative Data (2017-2025) |
|
|